ArticleBMC biology2025
HNF-DDA: subgraph contrastive-driven transformer-style heterogeneous network embedding for drug-disease association prediction.
Article in BMC biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- DMAPLM: A multimodal pretrained framework for computational drug repositioning.PLoS computational biology · 2026Article
- Transformer-based prediction of radiotherapy couch shift risk in prostate cancer based on rectal volume.Scientific reports · 2026Article
- MRDDA: a multi-relational graph neural network for drug-disease association prediction.Journal of translational medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundDrug-disease association (DDA) prediction aims to identify potential links between drugs and diseases, facilitating the discovery of new therapeutic potentials and reducing the cost and time associated with traditional drug development. However, existing DDA prediction methods often overlook the global relational information provided by other biological entities, and the complex association structure between drug diseases, limiting the potential correlations of drug and disease embeddings.
resultsIn this study, we propose HNF-DDA, a subgraph contrastive-driven transformer-style heterogeneous network embedding model for DDA prediction. Specifically, HNF-DDA adopts all-pairs message passing strategy to capture the global structure of the network, fully integrating multi-omics information. HNF-DDA also proposes the concept of subgraph contrastive learning to capture the local structure of drug-disease subgraphs, learning the high-order semantic information of nodes. Experimental results on two benchmark datasets demonstrate that HNF-DDA outperforms several state-of-the-art methods. Additionally, it shows superior performance across different dataset splitting schemes, indicating HNF-DDA's capability to generalize to novel drug and disease categories. Case studies for breast cancer and prostate cancer reveal that 9 out of the top 10 predicted candidate drugs for breast cancer and 8 out of the top 10 for prostate cancer have documented therapeutic effects.
conclusionsHNF-DDA incorporates all-pairs message passing and subgraph capture strategies into heterogeneous network embedding, enabling effective learning of drug and disease representations enriched with heterogeneous information, while also demonstrating significant potential for applications in drug repositioning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.